Effect of OKY-046 (thromboxane A2 synthetase inhibitor) on exercise-induced asthma.
The influence of OKY-046, which is a thromboxane (TxA2) synthetase inhibitor, was studied in patients with exercise-induced asthma (EIA). When OKY-046 was administered to 11 patients with EIA-positive (EIA+) asthma, 7 patients showed an effect of the inhibition of airway contraction. As the mechanism of action, inhibition of TxA2 production and acceleration of PGI2 were considered, since OKY-046 has no bronchodilation action. In other words, the fact that TxA2 was a mediator of EIA had been made clear, but it was also found that it had no association as a mediator of leukotrienes (LTC4 and LTB4) in EIA.
Hoshino
M
M
Second Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan.
Fukushima
Y
Y
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000328:Adult; D001250:Asthma, Exercise-Induced / Q000188:drug therapy*; D004341:Drug Evaluation; D005080:Exercise Test; D005260:Female; D006801:Humans; D007975:Leukotriene B4 / Q000097:blood; D008297:Male; D008689:Methacrylates / Q000627:therapeutic use*; D013189:SRS-A / Q000097:blood; D013928:Thromboxane A2 / Q000502:physiology*; D013929:Thromboxane B2 / Q000097:blood; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D008689:Methacrylates; D013189:SRS-A; D007975:Leukotriene B4; D013929:Thromboxane B2; D013928:Thromboxane A2; D015121:6-Ketoprostaglandin F1 alpha; D013930:Thromboxane-A Synthase; C034364:ozagrel